AU2400692A - Trifunctional compounds having specificity for multi-drug resistant cells - Google Patents

Trifunctional compounds having specificity for multi-drug resistant cells

Info

Publication number
AU2400692A
AU2400692A AU24006/92A AU2400692A AU2400692A AU 2400692 A AU2400692 A AU 2400692A AU 24006/92 A AU24006/92 A AU 24006/92A AU 2400692 A AU2400692 A AU 2400692A AU 2400692 A AU2400692 A AU 2400692A
Authority
AU
Australia
Prior art keywords
fab
agent
trifunctional compound
compound
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24006/92A
Other languages
English (en)
Inventor
Clarence N Ahlem
Lana S Grauer
Ann E. Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of AU2400692A publication Critical patent/AU2400692A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU24006/92A 1991-07-19 1992-07-17 Trifunctional compounds having specificity for multi-drug resistant cells Abandoned AU2400692A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73296991A 1991-07-19 1991-07-19
US732969 1991-07-19

Publications (1)

Publication Number Publication Date
AU2400692A true AU2400692A (en) 1993-02-23

Family

ID=24945654

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24006/92A Abandoned AU2400692A (en) 1991-07-19 1992-07-17 Trifunctional compounds having specificity for multi-drug resistant cells

Country Status (4)

Country Link
EP (1) EP0596011A1 (fr)
AU (1) AU2400692A (fr)
CA (1) CA2113578A1 (fr)
WO (1) WO1993002105A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3691093A (en) * 1992-04-14 1993-10-21 Hybritech Incorporated Methods of inhibiting the growth of multidrug resistant tumors
US5342926A (en) * 1993-06-08 1994-08-30 The Regents Of The University Of California Analogs of cytochalasin B as radiopharmaceuticals for nuclear imaging of trans-membrane glucose transport
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
DE19505960A1 (de) * 1995-02-21 1996-08-22 Deutsches Krebsforsch Konjugat zur individuellen Dosierung von Arzneimitteln
DE19531348A1 (de) * 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Antikörper mit zwei oder mehr Spezifitäten zur selektiven Eliminierung von Zellen in vivo
WO2000002050A1 (fr) * 1998-07-07 2000-01-13 Department Of Radiation Oncology, University Of Washington Reactif trifonctionnel pour la conjugaison avec une biomolecule
US20010023288A1 (en) 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
WO2000014537A2 (fr) * 1998-09-04 2000-03-16 Immunomedics, Inc. Diagnostic de resistance a plusieurs medicaments dans des lesions infectieuses et cancereuses
CA2386029A1 (fr) 1999-09-28 2001-04-05 Gentest Corporation P-glycoproteines provenant de <i>macaca fascicularis</i> et utilisations correspondantes
IT1319168B1 (it) * 2000-03-17 2003-09-26 Indena Spa Derivati di condensazione ad attivita' antitumorale, loro metodo dipreparazione e formulazioni che li contengono.
WO2002074048A2 (fr) 2001-03-19 2002-09-26 Gentest Corporation Glycoproteines p et leurs utilisations
WO2010011096A2 (fr) * 2008-07-23 2010-01-28 Hanmi Pharmaceutical Co., Ltd. Complexe de polypeptide comprenant un polymère non-peptidylique ayant trois extrémités fonctionnelles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722892A (en) * 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
IL97459A0 (en) * 1990-03-09 1992-06-21 Hybritech Inc Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent

Also Published As

Publication number Publication date
EP0596011A1 (fr) 1994-05-11
CA2113578A1 (fr) 1993-02-04
WO1993002105A1 (fr) 1993-02-04

Similar Documents

Publication Publication Date Title
US4863713A (en) Method and system for administering therapeutic and diagnostic agents
EP0550663B1 (fr) Anticorps modifies a temps de clairance regule
AU613318B2 (en) Affinity enhancement system
US5922847A (en) Methods of purifying hematopoietic cells using an antibody to a stem cell factor receptor
KR0135632B1 (ko) 감염성 및 염증성 병변 표적용 항-백혈구 결합체 및 이를 함유하는 제제 및 키트
CA2031129C (fr) Anticorps chimere pour la detection et le traitement de lesions infectieuses et inflammatoires
JP2968474B2 (ja) 抗−ヒト乳癌モノクローナル抗体を産生するハイブリドーマ
US5034223A (en) Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
USRE38008E1 (en) Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
PT94565B (pt) Novos anticorpos reactivos com carcinomas humanos
JPH04502702A (ja) ヒト癌に対する新規なモノクローナル抗体
AU2400692A (en) Trifunctional compounds having specificity for multi-drug resistant cells
AU616161B2 (en) Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
CA2066031C (fr) Methodes de reduction de la retention non recherchee d&#39;immunoconjugues et metabolites obtenus
Vacca et al. Imaging of human leukemic T‐Cell Xenografts in nude mice by radiolabeled monoclonal antibodies and F (ab') 2 fragments
US5250297A (en) Tumor-associated antigen, antibodies, compositions and uses therefor
US6440733B1 (en) Monoclonal antibodies recognizing antigens on the surface of endothelial cells of tumor vessel
JPH01502195A (ja) 細胞毒性結合物の増強法
Li et al. Preparation of antigastric cancer monoclonal antibody MGb2-mitomycin C conjugate with improved antitumor activity
EP0356397A2 (fr) Anticorps monoclonaux et antigène de surface cellulaire de carcinome pulmonaire
EP0424107A1 (fr) Un antigène nouveau associé aux tumeurs
de Jonge et al. Radioimmunodetection of human small cell lung carcinoma xenografts in the nude rat using 111in-labelled monoclonal antibody MOC-31
KITAMURA et al. Binding, internalization and the cytotoxicity of monoclonal antibody A7-neocarzinostatin conjugates (A7-NCS) in target cells
Endo et al. Tumor imaging by monoclonal antibodies labeled with radioactive metal ions
PL168711B1 (pl) Sposób wytwarzania rekombinantu nowego przeciwciala obejmujacego region wiazaniantygenu mysiego przeciwciala monoklonalnego BR 96 PL